Kristyn Galbraith, Mekka Garcia, Siyu Wei, Anna Chen, Chanel Schroff, Jonathan Serrano, Donato Pacione, Dimitris G Placantonakis, Christopher M William, Arline Faustin, David Zagzag, Marissa Barbaro, Maria Del Pilar Guillermo Prieto Eibl, Mitsuaki Shirahata, David Reuss, Quynh T Tran, Zahangir Alom, Andreas von Deimling, Brent A Orr, Erik P Sulman, John G Golfinos, Daniel A Orringer, Rajan Jain, Evan Lieberman, Yang Feng, Matija Snuderl
INTRODUCTION: IDH mutant astrocytoma grading, until recently, has been entirely based on morphology. The 5th edition of the Central Nervous System WHO introduces CDKN2A/B homozygous deletion as a biomarker of grade 4. We sought to investigate the prognostic impact of DNA methylation-derived molecular biomarkers for IDH mutant astrocytoma. METHODS: We analyzed 98 IDH mutant astrocytomas diagnosed at NYU Langone Health between 2014 and 2022. We reviewed DNA methylation subclass, CDKN2A/B homozygous deletion, and ploidy and correlated molecular biomarkers with histological grade, progression free (PFS), and overall (OS) survival...
January 19, 2024: Neuro-oncology